In focus · trending topic

janssen

13 stories · following the connections

Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates

By Nasdaq OMXMar 12, 2018, 11:30 AM UTC

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder

By Nasdaq OMXSep 5, 2017, 12:00 PM UTC

Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates

By Nasdaq OMXAug 3, 2017, 11:30 AM UTC

Minerva Announces Amended Agreement for MIN-202 in Insomnia

By Nasdaq OMXMay 31, 2017, 8:14 PM UTC

Minerva Announces Amended Agreement for MIN-202 in Insomnia

By Nasdaq OMXMay 31, 2017, 8:14 PM UTC

Minerva Announces Amended Agreement for MIN-202 in Insomnia

By Nasdaq OMXMay 31, 2017, 8:14 PM UTC

Minerva Announces Amended Agreement for MIN-202 in Insomnia

By Nasdaq OMXMay 31, 2017, 8:14 PM UTC

Minerva Announces Amended Agreement for MIN-202 in Insomnia

By Nasdaq OMXMay 31, 2017, 8:14 PM UTC